PROTEKT 1999-2000: a multicentre study of the antibiotic susceptibility of respiratory tract pathogens in Hong Kong, Japan and South Korea.
A multicentre surveillance study performed in the Far East during 1999-2000 investigated the in vitro activity of >20 antibacterials against common respiratory pathogens. In Hong Kong, Japan, and South Korea, 57.1, 44.5 and 71.5% Streptococcus pneumoniae were penicillin-resistant and 71.4, 77.9 and 87.6% were erythromycin-resistant, respectively. Overall, >90% of penicillin-resistant strains were also macrolide-resistant. All strains were susceptible to telithromycin. Fluoroquinolone-resistant isolates in Japan (1.3%), Hong Kong (14.3%) and South Korea (2.9%) were mostly co-resistant to penicillin, macrolides and tetracycline. Beta-lactamase production by Haemophilus influenzae isolates was 8.5% in Japan, 17.1% in Hong Kong and 64.7% in strains from South Korea. A single (0.27%) BLNAR isolate was obtained in Japan. There was no fluoroquinolone resistance. Moraxella catarrhalis was inhibited by telithromycin at <or=0.5mg/l and remained susceptible to macrolides, fluoroquinolones and amoxicillin-clavulanate. Resistance to antibacterials, particularly penicillin and macrolides, has reached high but stable levels in the Far East and the presence of multiply-resistant pneumococci is well established.
Inoue
Matsuhisa
M
Department of Microbiology, Kitasato University School of Medicine, 1-15-1 Kitasato Sagamihara, Kanagawa 228-8555, Japan. matsu@kitasato-u.ac.jp
Lee
Nam Yong
NY
Hong
Seto Wing
SW
Lee
Kyungwon
K
Felmingham
David
D
D024881:Drug Resistance, Bacterial / Q000502:physiology; D006192:Haemophilus Infections / Q000188:drug therapy / Q000201:enzymology / Q000453:epidemiology; D006193:Haemophilus influenzae / Q000187:drug effects* / Q000201:enzymology / Q000302:isolation & purification; D006723:Hong Kong / Q000453:epidemiology; D006801:Humans; D007564:Japan / Q000453:epidemiology; D007723:Korea / Q000453:epidemiology; D018942:Macrolides / Q000494:pharmacology* / Q000627:therapeutic use; D008826:Microbial Sensitivity Tests; D001936:Moraxella catarrhalis / Q000187:drug effects* / Q000201:enzymology / Q000302:isolation & purification; D011159:Population Surveillance / Q000379:methods; D012141:Respiratory Tract Infections / Q000188:drug therapy / Q000201:enzymology / Q000453:epidemiology; D013296:Streptococcus pneumoniae / Q000187:drug effects*; D001618:beta-Lactamases / Q000378:metabolism
D018942:Macrolides; D001618:beta-Lactamases